Quinn Anthony G.'s Form 4 filing
Spyre Therapeutics, Inc. (SYRE) · filed Dec 13, 2021
- Accession no.
- 0001209191-21-069350
- Filed
- Dec 13, 2021
- Trade date
- Dec 9-10, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market purchases total $199.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Quinn Anthony G.CIK 0001532219 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2021 | Common Stock | PPurchaseAcquired | +43,108 | $3.70 | +$159,499.6 | 318,269 | Direct | |
| Dec 10, 2021 | Common Stock | PPurchaseAcquired | +10,526 | $3.75 | +$39,472.5 | 328,795 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.